Lazertinib Matches Osimertinib Efficacy in First-Line EGFR‑Mutant Advanced NSCLC: Exploratory Results from MARIPOSA
In the MARIPOSA randomized, double-blind exploratory analysis, lazertinib monotherapy showed comparable progression-free survival, response rates, overall survival (interim), and tolerability to osimertinib in treatment-naive EGFR‑mutant advanced NSCLC, with fewer QT prolongation events.